Abstract
Cellular senescence increases with age and contributes to age-related declines and pathologies. We identified circulating biomarkers of senescence associated with diverse clinical traits in humans to facilitate future non-invasive assessment of individual senescence burden and efficacy testing of novel senotherapeutics. Using a novel nanoparticle-based proteomic workflow, we profiled the senescence-associated secretory phenotype (SASP) in monocytes and examined these proteins in plasma samples (N = 1060) from the Baltimore Longitudinal Study of Aging (BLSA). Machine learning models trained on monocyte SASP associated with several age-related phenotypes in a test cohort, including body fat composition, blood lipids, inflammation, and mobility-related traits, among others. Notably, a subset of SASP-based predictions, including a ‘high impact’ SASP panel that predicts age- and obesity-related clinical traits, were validated in InCHIANTI, an independent aging cohort. These results demonstrate the clinical relevance of the circulating SASP and identify relevant biomarkers of senescence that could inform future clinical studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute on Aging (NIA) Intramural Research Program (IRP), NIH. N.B. was supported by a SenNet NIH Common Fund Grant (NIA U54 AG079779, PI: Elisseeff) and a Hevolution GRO grant (HF-GRO-23-1199068-44).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The BLSA protocol (03AG0325) was approved by the institutional review board of the National Institute of Environmental Health Science, part of the National Institutes of Health. The BLSA approved and provided access to the BLSA study data. InCHIANTI study (exemption #11976) protocol was approved by Medstar Research Institute (Baltimore, Maryland), the Italian National Institute of Research and Care of Aging Institutional Review, and the Internal Review Board of the National Institute for Environmental Health Sciences (NIEHS). The InCHIANTI study team approved and provided access to the InCHIANTI study data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data Availability: All raw mass spectrometry data files and associated quantitative and statistical reports, metadata, and supplemental data are available on MassIVE (dataset identifier: MSV000095315). FTP download link: ftp://massive.ucsd.edu/v08/MSV000095315/.
Code Availability: R scripts for the core elastic net analysis described are available at https://github.com/geroproteomics/EN_Repeat/blob/main/EN_Repeat.
Other data are available upon reasonable request to the authors.
ftp://massive.ucsd.edu/v08/MSV000095315/
https://github.com/geroproteomics/EN_Repeat/blob/main/EN_Repeat.
